83rd Annual Meeting of the American Thyroid AssociationMeeting Abstracts & Program
2013; Mary Ann Liebert, Inc.; Volume: 23; Issue: S1 Linguagem: Inglês
10.1089/thy.2013.2310.abs
ISSN1557-9077
Tópico(s)Medical and Biological Sciences
ResumoThyroidVol. 23, No. S1 AbstractsFree Access83rd Annual Meeting of the American Thyroid AssociationMeeting Abstracts & ProgramPublished Online:8 Oct 2013https://doi.org/10.1089/thy.2013.2310.absAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Scientific Meeting Program (as of 9/3/2013)WEDNESDAY, OCTOBER 16, 20137:00 a.m. – 4:00 p.m.20th Endocrine Fellows Conference (Satellite program, separate registration required)7:00 a.m. – 5:00 p.m.ATA/AACE Endocrine Neck UltrasoundWorkshop and Practicum (Satellite program, separate registration required)8:30 a.m. – 2:00 p.m.ATA Board of Directors' Meeting2:00 p.m. – 8:30 p.m.Registration Open5:30 p.m. – 5:45 p.m.Welcome to the 83rd Annual Meeting of the ATA Bryan R. Haugen, ATA President John C. Morris, ATA Secretary/COO Ronald Koenig, ATA Program Committee Co-Chair Julie Ann Sosa, ATA Program Committee Co-Chair5:45 p.m. – 7:30 p.m.Opening Session: Recent Developments and Future Challenges in Thyroidology Chairs: Ronald Koenig and Julie Ann Sosa Basic ReviewAnthony Hollenberg Clinical Endocrine ReviewMegan Haymart Surgical ReviewDavid Steward7:30 p.m. – 9:00 p.m.Welcome Reception Join us for a relaxed time with old friends and a chance to greet new ATA members.8:30 p.m. – 9:30 p.m.ATA Trainees' Welcome Reception--------------------------------------------THURSDAY, OCTOBER 17, 20136:30 a.m. – 5:30 p.m.Registration Open6:30 a.m. – 7:30 a.m.Early Riser SymposiumContinental Breakfast6:45 a.m. – 8:00 a.m.Early Riser ICCIDD Symposium: Iodine Chair: Elizabeth Pearce Iodine Status of Europe 2013John Lazarus Coordinating Sodium Reduction and Salt Iodization ProgramsEduardo Pretell Iodine Deficiency and Child Cognition in the United KingdomMargaret Rayman8:05 a.m. – 8:10 a.m.Welcome and Announcements Bryan R. Haugen, John C. Morris, Ronald Koenig and Julie Ann Sosa8:10 a.m. – 8:55 a.m.Plenary Lecture: The Application of Integrative Sequencing for Precision OncologyArul Chinnaiyan Introduction: Ronald Koenig9:00 a.m. – 10:00 a.m.Highlighted Oral Abstract Session (4 total) Chairs: Ronald Koenig and Julie Ann Sosa Highlighted Oral 1Thyroid Hormone Metabolism & RegulationBasic THE ROLE OF NCOR AND SMRT IN THYROID HORMONE ACTION AND METABOLIC DISEASE H. Shimizu, I. Astapova, P. Ramadoss, K. Vella, F. Ye, M. Bilban, R. Cohen, A.N. Hollenberg Highlighted Oral 2Thyroid Hormone Metabolism & RegulationBasic BOTH SKELETAL MYOCYTES AND ADIPOCYTES EXPRESS THE TYPE 2 DEIODINASE WITHIN SKELETAL MUSCLE J.S. Werneck-de-Castro, T. Fonseca, D.L. Ignacio, G. Fernandes, M. Baldanza, I.F. Rangel, G. Balazs, M.F. Miranda, C. Andrade, A. Bianco Highlighted Oral 3AutoimmunityClinical RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RITUXIMAB FOR TREATMENT OF GRAVES’ OPHTHALMOPATHY M.N. Stan, J.A. Garrity, P. Thapa, E.A. Bradley, R.S. Bahn Highlighted Oral 4Thyroid CancerClinical CORRELATIVE ANALYSES OF RET AND RAS MUTATIONS IN A PHASE 3 STUDY OF CABOZANTINIB IN PATIENTS (PTS) WITH PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC) M.S. Brose, S.I. Sherman, P. Schöffski, R. Elisei, M. Schlumberger, L. Wirth, M. Mangeshkar, D.T. Aftab, D.O. Clary, E.E. Cohen10:00 a.m. – 4:30 p.m.Exhibit Hall Open10:00 a.m. – 11:00 a.m.Poster Review Session and Break in the Exhibit Hall11:00 a.m. – 12:00 p.m.Meet the Professor Workshops Clinical: Management of Pediatric Thyroid Nodules and CancerStephen Huang/ Geoffrey Thompson Clinical: Weird TFTs, Their Interpretation and ManagementMarius Stan/ Jeffrey Garber Clinical: Management of Poorly Differentiated/Anaplastic Carcinoma and Thyroid LymphomaNaifa Busaidy/ Julie Ann Sosa Basic: Update on the Biology of 3-Iodothyronamine (T1AM)Thomas Scanlan/ Riccardo Zucchi Basic: Update on Thyroid Hormone TransportersEdward Visser/ Heike Heuer12:00 p.m. – 12:55 p.m.Poster Review and Lunch on your Own12:00 p.m. – 12:55 p.m.ATA Expo Theater Presentation with Veracyte, Inc. — The Afirma Thyroid FNA Analysis: Rationale and Benefits of a Patient-Centric Approach to Thyroid Nodule Management Speakers: Richard T. Kloos and Anagh Vora12:00 p.m. – 12:55 p.m.ATA Committee Meetings/Luncheon (For Active 2013 ATA Committee Members – see governance listing in program book for room assignments)1:00 p.m. – 1:45 p.m.Sidney H. Ingbar Award Lecture: PAX8-PPARgamma Fusion Protein in Thyroid CancerRonald Koenig Introduction: P. Reed Larsen1:50 p.m. – 3:20 p.m.Basic/TranslationalOral Abstract Session Chairs: Honey Reddi and Antonio Di Cristofano Oral 5Iodine Uptake & MetabolismTranslational SYSTEMIC EPIDERMAL GROWTH FACTOR RECEPTOR-TARGETED SODIUM IODIDE SYMPORTER (NIS) GENE THERAPY IN A GENETICALLY ENGINEERED MOUSE MODEL OF PANCREATIC DUCTAL ADENOCARCINOMA G. Gruenwald, M. Traikovic-Arsic, K. Klutz, A. Gupta, N. Schwenk, K. Knoop, R. Braren, M. Settles, R. Senekowitsch-Schmidtke, M. Schwaiger, E. Wagner, B. Göke, M. Ogris, J. Siveke, C. Spitzweg Oral 6Thyroid CancerBasic HUMAN ANAPLASTIC THYROID CARCINOMA CELL LINES ARE SENSITIVE TO LYSIS BY NK CELLS CORRELATING WITH HIGH EXPRESSION OF THE NKG2D LIGAND UL 16 BINDING PROTEIN 2 ON TUMOR CELLS E. Wennerberg, L. Ekblad, C. Juhlin, A. Höög, V. Sviatoha, J. Zedenius, C. Larsson, V.O. Kaminskyy, B. Zhivotovsky, J. Wennerberg, A. Lundqvist Oral 7Thyroid CancerTranslational ROLE OF MIR-145 IN THYROID CANCER GROWTH, METASTASIS, AND DIAGNOSIS M. Boufraqech, L. Zhang, M. Jain, D. Patel, R. Ellis, Y. Xiong, M. He, N. Nilubol, M. Merino, E. Kebebew Oral 8Thyroid DevelopmentBasic THYROID TRANSPLANTATION USING EMBRYONIC STEM CELLS R. Ma, R. Latif, T.F. Davies Oral 9Thyroid Hormone ActionBasic MUTATION OF NCOR1 CORRECTS THE RESISTANCE TO THYROID HORMONE PHENOTYPE IN SRC-1 KNOCKOUT MICE VIA SRC-2 K. Vella, I. Astapova, F. Ye, A.N. Hollenberg Oral 10Thyroid Hormone ActionBasic A HISTONE DEACETYLASE INHIBITOR AMELIORATES IMPAIRED BONE DEVELOPMENT AND ADIPOGENESIS CAUSED BY A TRα1 MUTANT IN A MOUSE MODEL D. Kim, J. Park, S. Cheng1:50 p.m. – 3:20 p.m.ClinicalOral Abstract Session Chairs: Emad Kandil and Naifa Busaidy Oral 11AutoimmunityClinical THYROID PEROXIDASE ANTIBODY-PREVALENCE AND PRETERM DELIVERY RATE IN DANISH PREGNANT WOMEN BEFORE, DURING, AND AFTER NATIONAL IODINE IMPLEMENTATION - A COMPARATIVE COHORT STUDY S. Bliddal, U. Feldt-Rasmussen, M. Boas, J. Faber, A. Juul, T. Larsen, L. Friis-Hansen, L. Hilsted, A. Tabor, D.P. Hansen Oral 12AutoimmunityClinical MEASUREMENT OF SERUM IGG4 CONCENTRATIONS IN PATIENTS WITH GRAVES’ DISEASE; CLINICAL CHARACTERISTICS OF THOSE WITH ELEVATED IGG4 LEVELS K. Takeshima, H. Inaba, Y. Furukawa, H. Yamaoka, M. Nishi, T. Akamizu Oral 13Thyroid CancerTranslational TARGETED NEXT-GENERATION SEQUENCING (THYROSEQ) FOR DIAGNOSIS OF THYROID CANCER M.N. Nikiforova, A. Wald, S.P. Hodak, S.E. Carty, Y.E. Nikiforov Oral 14Thyroid DevelopmentClinical ABNORMAL CORPUS CALLOSUM MORPHOLOGY IN CONGENITAL HYPOTHYROIDISM F. Islam, J. Skocic, J.F. Rovet Oral 15Thyroid DevelopmentClinical A COMPARISON OF URINARY IODINE CONCENTRATIONS BETWEEN BREASTFED AND FORMULA-FED INFANTS J.H. Gordon, A.M. Leung, A.R. Hale, E.N. Pearce, L.E. Braverman, X. He, M.B. Belfort, S.M. Nelson Oral 16Thyroid Nodules & GoiterClinical MULTICENTER CLINICAL EXPERIENCE WITH THE AFIRMA GENE EXPRESSION CLASSIFIER E. Alexander, M. Schorr, J. Klopper, C. Kim, J. Sipos, F. Nabhan, C. Parker, D. Steward, S. Mandel, B. Haugen3:20 p.m. – 3:50 p.m.Poster Review Session andBreak in the Exhibit Hall3:50 p.m. – 5:05 p.m.Clinical: Thyroid, Pregnancy, and the Offspring Chair: Alex Stagnaro-Green Generic and Brand-Name L-Thyroxine Are Not Bioequivalent for Children with Severe Congenital HypothyroidismRosalind Brown Maternal Autoimmune Thyroid Disease and the Risk of Attention Deficit-Hyperactivity Disorder (ADHD) in OffspringAkhgar Ghassabian Update on Hypothyroxinemia of PrematurityAleid van Wassenaer-Leemhuis3:50 p.m. – 5:05 p.m.Basic:Thyroid Hormone Control of Metabolism Chair: Brian Kim Thyroid Hormone Regulation of Lipid MetabolismPaul Yen Central Control of Metabolism by Thyroid HormoneMiguel Lopez Thyroid Hormone and SirtuinsPieter de Lange5:10 p.m. – 6:25 p.m.Symposium: Molecular Underpinnings of Thyroid Cancer Development and Growth Chair: Mingzhao Xing The Cancer Genome Atlas (TCGA): Analysis of Papillary Thyroid CarcinomasThomas Giordano Large Non-Coding RNAs: Novel Genes Involved in Papillary Thyroid Carcinomas PathogenesisJaroslaw Jendrzejewski MicroRNA Regulates TGFbeta Signaling in Thyroid CancerEdna T. Kimura6:30 p.m. – 7:30 p.m.ATA Annual Business Meeting (For Active ATA members only) The annual business meeting will feature election results, committee reports, revised bylaws vote and discussion of important member issues.------------------------------------------------FRIDAY, OCTOBER 18, 20136:30 a.m. – 5:30 p.m.Registration Open6:30 a.m. – 7:30 a.m.Early Riser SymposiumContinental Breakfast6:45 a.m. – 8:00 a.m.Early Riser Symposium: Diagnostic Testing of Thyroid Nodules Chair: Shereen Ezzat Overview of Indeterminant CytologyScott Boerner Molecular Markers in Thyroid NodulesYuri Nikiforov Comparison of Commercially Available Tests in the Molecular Analysis of Thyroid NodulesStefan Grebe8:05 a.m. – 8:10 a.m.Announcements Program Chairs Ronald Koenig and Julie Ann Sosa8:10 a.m. – 8:55 a.m.Van Meter Lecture (announced onsite at time of lecture) Established in 1930, recognizes outstanding contributions to research on the thyroid gland or related subjects. The award is given each year to an investigator who is not older than the age of 45 in the year of the award. The Van Meter award winner is kept secret until the time of the award lecture during the annual meeting. This award received support from Mary Ann Liebert, Inc. Publishers.9:00 a.m. – 10:15 a.m.Clinical: Graves' Disease Chair: Kenneth Burman Update on Immunopathogenesis of Graves' OphthalmopathyTerry Smith Rituximab in Graves' OphthalmopathyMario Salvi Predictive Score for Recurrence Risk after Antithyroid Drugs Based on Baseline Clinical and Genetic ParametersWilmar Wiersinga9:00 a.m. – 10:15 a.m.Basic: Molecular Mechanisms of Thyroid Hormone Action Chair: Inna Astapova Differential Regulation of Gene Expression by TRa1 vs. TRb1Frédéric Flamant Thyroid Hormone Receptors in the Skin and Skin CarcinogenesisAnn Aranda The Role of Histone Modification in Thyroid Hormone ActionYun-Bo Shi10:00 a.m. – 4:30 p.m.Exhibit Hall Open10:15 a.m. – 11:15 a.m.Poster Review Session andBreak in the Exhibit Hall11:15 a.m. – 12:30 p.m.Arthur Bauman Clinical Symposium: Every Day Ethical Dilemmas for Thyroid Practitioners Chair: Loren Wissner Greene Ethical Issues in Robotic Transaxillary ThyroidectomyPeter Angelos Ethical Challenges with Tyrosine Kinase Inhibitors for Thyroid Cancer: Costs, Therapeutic Benefits, and Distributive JusticeKeith Bible The Limits of Autonomy in Thyroid Disease ManagementM. Sara Rosenthal11:15 a.m. – 12:30 p.m.Basic: Thyroid Hormone and Neurobiology Chair: Frédéric Flamant T3 and Neural Stem Cell CommitmentBarbara Demeneix T3/TRa1 in Hypothalamic Development and Cardiovascular FunctionBjorn Vennstrom Visual/Hearing System DevelopmentDouglas Forrest12:30 p.m. – 1:25 p.m.Poster Review and Lunch on your Own12:30 p.m. – 1:25 p.m.ATA Expo Theater Presentation with MedImmune, Specialty Care Division of AstraZeneca — Discussing a Treatment Option for a Rare Disease: Advanced Medullary Thyroid Cancer Speaker: Hari A. Deshpande1:30 p.m. – 2:15 p.m.Lewis E. Braverman Award Lecture: Enhancing Iodide Transport in Thyroid & Breast CancerGregory A. Brent Introduction: Susan Mandel2:20 p.m. – 3:20 p.m.Meet the Professor Workshops Clinical: Duration of Anti-Thyroid Drug Treatment in Graves' Disease: Children vs. AdultsJuliane Leger/ David Cooper Clinical: Thyroid Cancer in PregnancyErik Alexander/ Sanziana Roman Clinical: Management of Thyroid Disease in the ElderlyKristien Boelaert/ Linwah Yip Basic: The Sodium Iodide Symporter in Non-Thyroid CancerJamila Faivre/John Morris Translational: The Nonthyroidal Illness Syndrome: Clinical Management and Basic MechanismsVirginia Sarapura/ Anita Boelen3:25 p.m. – 3:50 p.m.Clark T. Sawin Historical Vignette: Italian Thyroidology – Renaissance to PincheraFurio Pacini Introduction: Lewis Braverman Dedicated to the memory of Aldo Pinchera The Clark T. Sawin History Resource Center supports this historical lecture and memorializes the work of Dr. Sawin, who served as chair of the history and archives committee for many years; and as the presenter of the historical vignette at ATA annual meetings from 1993–2003; and as president of the ATA 2003–2004.3:50 p.m. – 4:20 p.m.Poster Review Session andBreak in the Exhibit Hall4:20 p.m. – 5:05 p.m.Research Grants Symposium Chair: Christine Spitzweg Targeting BRAFV600E with an Orally Available Selective Inhibitor in Novel in vitro and in vivo Preclinical Models of Human Papillary Thyroid CancerCarmelo Nucera Elucidating the in vivo Mechanisms by which Thyroid Hormone Regulates Energy ExpenditureInna Astapova The Role of the Translocator Protein (TSPO) in the Thyroid Cancer Response to the TreatmentJoanna Klubo-Gwiezdzinska5:10 p.m. – 6:40 p.m.Basic/Translational Oral Abstract Session Chairs: John A. Copland, III and Sheue-yann Cheng Oral 90AutoimmunityBasic TSH RECEPTOR TRANSMEMBRANE- ”HOTSPOTS” FOR THYROID STIMULATION REVEALED BY SMALL MOLECULE AGONISM R. Latif, S.A. Morshed, M. Ali, T.F. Davies Oral 91AutoimmunityTranslational CROSS-COMMUNICATION BETWEEN IGF-1R AND TSHR IN ORBITAL FIBROBLASTS FROM PATIENTS WITH GRAVES’ OPHTHALMOPATHY (GO) S. Kumar, M. Coenen, S. Iyer, P. Chiriboga, R.S. Bahn Oral 92AutoimmunityTranslational GENETIC VARIANTS ASSOCIATED WITH THYROID AUTOIMMUNITY AND CLINICAL THYROID DISEASE: NEW INSIGHTS FROM A GENOME WIDE META-ANALYSIS IN 27,000 SUBJECTS M. Medici, E. Porcu, G. Pistis, A. Teumer, S. Brown, R. Jensen, R. Rawal, G. Roef, J. Lahti, M. Simmonds, L. Husemoen, R. Freathy, B. Shields, D. Pietzner, R. Nagy, B. Psaty, A. de la Chapelle, S. Gough, H. Meyer zu Schwabedissen, T. Frayling, A. Linneberg, K. Räikkönen, J. Smit, F. Rivadeneira, A. Uitterlinden, J. Walsh, C. Meisinger, M. den Heijer, T.J. Visser, S. Wilson, H. Völzke, A.R. Cappola, D. Toniolo, S. Sanna, S. Naitza, R. Peeters Oral 93Thyroid Hormone Metabolism & RegulationBasic ADIPOSE TISSUE-SPECIFIC INACTIVATION OF TYPE II DEIODINASE RAISES THE EXCHANGE RESPIRATORY RATIO AND INCREASES SUSCEPTIBILITY TO DIET-INDUCED OBESITY T. Fonseca, M. Castillo, J. Werneck de Castro, M. Correa-Medina, B. Bocco, G. Fernandes, E. McAninch, G. Balazs, C. Moises, A. Ferreira, A. Bianco Oral 94Thyroid Hormone Metabolism & RegulationBasic β-ARRESTIN 1 MEDIATES TSH RECEPTOR SIGNALING S. Neumann, E. Eliseeva, M.C. Gershengorn Oral 95Thyroid Hormone ActionBasic RAPID EFFECTS OF T3 ON POSTTRANSCRIPTIONAL STEPS OF TSH SYNTHESIS AND SECRETION IN TALPHAT1 CELL LINE AND PRIMARY CULTURE OF ANTERIOR PITUITARY CELLS P. Bargi-Souza, M. Kucka, I. Bjelobaba, F. Goulart-Silva, S.S. Stojilkovic, M. Nunes5:10 p.m. – 6:40 p.m.Clinical Oral Abstract Session Chairs: Joshua Klopper and Mabel Ryder Oral 96Thyroid CancerClinical OUTCOMES OF PATIENTS WITH POORLY DIFFERENTIATED THYROID CANCER OF FOLLICULAR ORIGIN TREATED WITH FIRST LINE SORAFENIB A. Adili, B. Chasen, R. Dadu, M. Williams, S.K. Ali, S.G. Waguespack, M.A. Habra, G. Cote, N. Busaidy, C. Jimenez, M.I. Hu, R.V. Sellin, S.I. Sherman, M.E. Cabanillas Oral 97Thyroid CancerClinical SURVIVAL AND EFFICACY OF SALVAGE TYROSINE KINASE INHIBITORS (TKIS) AFTER FIRST LINE SORAFENIB (SOR) FAILURE IN PATIENTS WITH ADVANCED DIFFERENTIATED THYROID CANCER (DTC) R. Dadu, C. Devine, M. Hernandez, N. Busaidy, S.G. Waguespack, M.I. Hu, A. Ying, M.A. Habra, C. Jimenez, R.V. Sellin, G. Cote, S. Sherman, M.E. Cabanillas Oral 98Thyroid CancerClinical OVERUTILIZATION OF RAI FOR VERY LOW RISK THYROID CANCER IS MOST FREQUENT IN REGIONS WITH POORER HEALTHCARE ACCESS J. Marti, R. Tuttle, L.G. Morris Oral 99Thyroid CancerTranslational IDENTIFICATION OF NEW DIAGNOSTIC MARKERS FOR CYSTIC PAPILLARY THYROID CARCINOMA: A PROTEOMICS APPROACH A. Dinets, M. Pernemalm, H. Eriksson, V. Sviatoha, A. Sofiadis, J. Zedenius, C. Larsson, J. Lehtiö, A. Höög Oral 100Thyroid CancerClinical PHASE III RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF SORAFENIB IN LOCALLY ADVANCED OR METASTATIC PATIENTS WITH RADIOACTIVE IODINE (RAI)-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC) - EXPLORATORY ANALYSES OF PATIENT-REPORTED OUTCOMES M. Schlumberger, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, F. Worden, A. Bockisch, C. Nutting, Y. Shong, S.I. Sherman, J. Smit, J. Chung, C. Kappeler, I. Molnar, K. Keating, D. Cella, M.S. Brose Oral 101Thyroid CancerTranslational NEXT GENERATION SEQUENCING IS FEASIBLE ON FINE-NEEDLE-ASPIRATION SPECIMENS AND IMPROVES THE DIAGNOSIS OF THYROID NODULES M. Le Mercier, N. D'Haene, N. De Nève, C. Degand, S. Rorive, I. Salmon7:30 p.m. – 11:00 p.m.ATA Annual Reception and Banquet Presentation of the ATA Distinguished Service Award2013 Awardee: Peter Singer In recognition and honor of a member who has made important and continuing contributions to the Association. Presentation of the John B. Stanbury Thyroid Pathophysiology Medal2013 Awardee:Theo Visser In recognition of outstanding research contributions, either conceptual or technical, to the understanding of thyroid physiology or the pathophysiology of thyroid disease, as evidenced by having a major impact on research or clinical practice related to thyroid diseases.------------------------------------------------SATURDAY, OCTOBER 19, 20136:30 a.m. – 5:30 p.m.Registration Open6:30 a.m. – 7:30 a.m.Early Riser SymposiumContinental Breakfast6:45 a.m. – 8:00 a.m.Early Riser Symposium: Ongoing Controversies in the Surgical Management of Thyroid Cancer Moderator: Gerard Doherty Is Prophylactic Central Neck Dissection Indicated for Papillary Thyroid Cancer?Sara Pai What are the Indications for Lateral Neck Dissection?Brendan Stack How Should Microcarcinomas be Handled in the Operating Room?Elizabeth Grubbs8:05 a.m. – 8:10 a.m.Announcements Program Chairs Ronald Koenig and Julie Ann Sosa8:10 a.m. – 8:55 a.m.Plenary Lecture: Embryonic Stem Cell Differentiation into a Functioning Thyroid GlandSabine Costagliola Introduction: Douglas Forrest9:00 a.m. – 10:30 a.m.Short Call Oral Abstracts Chairs: R. Michael Tuttle and Rebecca Schweppe Short Call Oral 1Thyroid Hormone Metabolism & Regulation Basic A SEQUENTIAL EXPRESSION OF D3 AND D2 DEIODINASES IS REQUIRED DURING SKELETAL MUSCLE REGENERATION M. Dentice, R. Ambrosio, C. Luongo, F. Alfano, D. Salvatore Short Call Oral 2Thyroid CancerBasic IDENTIFICATION OF ALK FUSIONS AS A POTENTIAL THERAPEUTIC TARGET IN AGGRESSIVE FORMS OF THYROID CANCER L.M. Kell, G. Barila; P. Liu, S. Trivedi, S.E. Carty, S. Hodak, M. Nikiforova, R.L. Ferris, D. Altschuler, Y. Nikiforov Short Call Oral 3Thyroid CancerTranslational INCREASING THE DIAGNOSTIC YIELD OF THYROID CANCER: A CASE-CONTROL STUDY IN OVER 600 PRE- AND POST-SURGICAL SPECIMENS E. Labourier, S. Beaudenon, D. Wylie, T. Giordano Short Call Oral 4Disorders of Thyroid FunctionTranslational CHILDREN BORN TO WOMEN WITH HYPOTHYROIDISM DURING PREGNANCY SHOW ABNORMAL CORPUS CALLOSUM DEVELOPMENT A. Samadi, J. Skocic, J. Rovet Short Call Oral 5Thyroid CancerClinical TSH SUPPRESSION INCREASES THE RISK OF OSTEOPOROSIS WITHOUT CHANGING RECURRENCE IN NON-HIGH RISK PATIENTS WITH THYROID CARCINOMA A.W. Smith, L.Y. Wang, F.L. Palmer, A. Mahrous, I. Ganly, S.G. Patel, R.M. Tuttle, J.A. Fagin, L. Boucai Short Call Oral 6Thyroid CancerClinical TERT PROMOTER MUTATION CORPORATES WITH BRAF MUTATION TO PROMOTE THYROID CANCER RECURRENCE M. Xing, X. Liu, R. Liu, S. I. Pai, M. Zeiger, J. Bishop9:30 a.m. – 1:30 p.m.Exhibit Hall Open10:30 a.m. – 11:30 a.m.Poster Review Session andBreak in the Exhibit Hall11:30 a.m. – 12:30 p.m.Meet the Professor Workshops Clinical: Congenital Hypothyroidism: Management of Mild Cases and Discovery of Novel Genetic CausesGuy Van Vliet/ Nadia Schoenmakers Clinical: Controversies in Perioperative Management: Outpatient Thyroidectomy and Calcium ManagementMaise Shindo/ Michael Yeh Clinical: Risk Stratification of Thyroid Cancer PatientsR. Michael Tuttle/ John Ridge Basic:Thyroid Hormone Regulation of Cholesterol and Liver MetabolismKevin Phillips/ Koshi Hashimoto Translational:Biorepositories and Electronic Registries for Clinical ResearchRobert Smallridge/ Michael Roehrl12:30 p.m. – 1:25 p.m.Poster Review and Lunch on your Own1:30 p.m.Exhibit Hall Closes1:30 p.m. – 2:15 p.m.Paul Starr Award Lecture: Thyroid Autoimmunity at 60: Where Next?Anthony Weetman Introduction: Graham Williams In recognition of an outstanding contributor to clinical thyroidology Supported by an educational grant from Dr. Boris Catz2:20 p.m. – 3:20 p.m.Basic/Translational Oral Abstract Session Chairs: Sissy Jhiang and Yuri Nikiforov Oral 179Thyroid CancerBasic COMBINED MAP KINASE AND SRC INHIBITION RESULTS IN ENHANCED ANTI-TUMOR EFFECTS IN PAPILLARY AND ANAPLASTIC THYROID CANCER T.C. Beadnell, B. Bowers, C. Chan, X. Jing, L.A. Pike, J. Tentler, J. Kim, A. Tan, R.E. Schweppe Oral 180Thyroid CancerTranslational PAZOPANIB RESISTANCE INDUCED BY IN VITRO SELECTION OF BHP2-7 PAPILLARY THYROID CANCER CELLS IS ASSOCIATED WITH ACQUIRED KRAS MUTATION AND MORE AGGRESSIVE IN VIVO PHENOTYPE C.R. Isham, B.C. Netzel, A.R. Bossou, D. Milosevic, K.W. Cradic, S.K. Grebe, K.C. Bible Oral 181Thyroid CancerBasic THE SONIC HEDGEHOG SIGNALING PATHWAY ENHANCES THE INVASIVENESS OF THYROID TUMOR CELLS BY THE ACTIVATION OF AKT AND C-MET: POTENTIALLY PROMOTING THYROID TUMOR STEM CELL SELF-RENEWAL A.J. Williamson, K. Heiden, R.A. Prinz, X. Xu Oral 182Thyroid Hormone ActionBasic THYROID HORMONE DRIVING LARVAL CELLS MAD: THE ROLE OF C-MYC GENE FAMILY IN THYROID HORMONE-DEPENDENT INTESTINAL STEM CELL DEVELOPMENT T.C. Miller, J. Chiu, L. Fu, Y. Shi2:20 p.m. – 3:20 p.m.Clinical Oral Abstract Session Chairs: Angela Leung and Michael McDermott Oral 183Disorders of Thyroid FunctionClinical METHIMAZOLE AND PROPYLTHIOURACIL EXPOSURE IN EARLY PREGNANCY ARE BOTH ASSOCIATED WITH AN INCREASED RISK OF BIRTH DEFECTS, BUT THE SPECTRUM OF MALFORMATIONS DIFFERS. A DANISH NATIONWIDE STUDY OF 817,093 CHILDREN S.L. Andersen, J. Olsen, C.S. Wu, P. Laurberg Oral 184Disorders of Thyroid FunctionClinical MATERNAL PERCHLORATE LEVELS DURING PREGNANCY AND OFFSPRING COGNITIVE DEVELOPMENT: DATA FROM THE CONTROLLED ANTENATAL THYROID SCREENING STUDY (CATS) P. Taylor, O.E. Okosieme, S. Channon, P. Smyth, C.M. Dayan, L.E. Braverman, J. Lazarus, E.N. Pearce Oral 185Disorders of Thyroid FunctionClinical WEIGHT CHANGE AFTER TREATMENT OF HYPOTHYROIDISM S.Y. Lee, L.E. Braverman, E.N. Pearce Oral 186Thyroid Hormone Metabolism & RegulationClinical THYROID HORMONE CIRCADIAN AND CIRCANNUAL VARIATION IN 475,000 OUTPATIENTS J. Ehrenkranz, P.R. Bach, S. Benvenga3:25 p.m. – 4:40 p.m.Clinical: Molecular Diagnostic Testing of Thyroid Nodules: Decision Making for the Clinician Chairs: Eren Berber and Emad Kandil Decision Making for the SurgeonRalph Tufano Decision Making for the EndocrinologistSusan Mandel/ Bryan McIver3:25 p.m. – 4:40 p.m.Basic: Importance of Regulated Tissue Thyroid Hormone Availability Chair: Anita Boelen Local Control of Thyroid Hormone Availability Regulates Cell ProliferationDomenico Salvatore Local Control of Thyroid Hormone Availability Regulates Cardiac Tissue RepairAntonio Bianco Local Control of Thyroid Hormone Availability Regulates Bone MaintenanceJ.H. Duncan Bassett4:40 p.m. – 4.55 p.m.CoffeeBreak4:55 p.m. – 6:10 p.m.Symposium: Early Stages of Thyroid Autoimmunity Chair: Rebecca Bahn Exposure to Environmental FactorsPeter Laurberg Interaction Between Genes and EnvironmentYaron Tomer Immune Response Markers in Serum Prior to the Occurrence of Thyroid AntibodiesMarjan Versnel------------------------------------------------SUNDAY, OCTOBER 20, 20137:30 a.m. – 8:30 a.m.Continental Breakfast8:00 a.m. – 11:30 a.m.Registration Open8:00 a.m. – 9:15 a.m.An Update on Novel Therapies for Advanced Thyroid Cancer: When to Start and What to Use Chair: Mimi Hu Overview of Drugs Approved, in Trial and in the Pipeline for Differentiated Thyroid CancerMarcia Brose Overview of Drugs Approved, in Trial and in the Pipeline for Medullary Thyroid CancerMatthew Ringel Case DiscussionsAnn Gramza9:30 a.m. – 11:00 a.m.Thyroid Cancer Tumor Board Session Moderator: Gregory Randolph EndocrinologyDavid Sarne SurgeryBarbra Miller Nuclear MedicineDouglas van Nostrand OncologyManisha Shah PathologySylvia Asa11:00 a.m.83rd Annual Meeting of the ATA EndsThursday, October 17, 2013Highlighted Oral 1 Thyroid Hormone Metabolism & Regulation Thursday Highlighted Oral Basic 9:00 AMTHE ROLE OF NCOR AND SMRT IN THYROID HORMONE ACTION AND METABOLIC DISEASEH. Shimizu 1, I. Astapova 1, P. Ramadoss 1, K. Vella 1, F. Ye 1, M. Bilban 2, R. Cohen 3, A.N. Hollenberg 11Endocrinology, Beth Israel Deaconess Medical Center, Boston, MA2Laboratory Medicine, Medical University of Vienna, Vienna, Austria3Endocrinology, Diabetes, and Metabolism, University of Chicago Medicine, Chicago, ILNuclear receptor co-repressor (NCoR) and silencing mediator of retinoid and thyroid hormone receptors (SMRT) are well-recognized co-repressors of the thyroid hormone receptor (TR) isoforms and other nuclear receptors. Defects in their function can lead to alterations in thyroid hormone (TH) signaling and metabolic dysfunction. Indeed, we have shown previously that deletion of NCoR function enhances TH action on TR target genes. However, whether NCoR or SMRT have have specific roles in TH action has never been tested previously in vivo.To test our hypothesis that NCoR is the specific corepressor for the TR we generated mice that lack functional NCoR (NCoRΔID), SMRT (SMRT−/−) or both (DKO) in the liver only using cre/lox technology and then assessed TH and metabolic signaling in either euthyroid or hypothyroid animals.Consistent with our hypothesis, the isolated deletion of SMRT in the liver had no effect on enhancing TH action in either the hypothyroid or euthyroid state on all TR target genes tested including fasn, thrsp, dio1, gpd2 and bcl3. In contrast and as seen previously the disruption of NCoR function greatly enhanced TH action on all TR targets. The phenotype of DKO mice in context of TH-signaling was similar to NCoRΔID mice confirming the dominant and necessary role of NCoR in TH action. To discern what role SMRT may be playing in the liver we further analyzed the phenotype of DKO mice. Remarkably, DKO mice have significant hepatic steatosis and decreased serum triglycerides compared to WT, NCoRΔID and SMRT−/− mice. Consistent with this, there was profound upregulation of both lipogeneic and lipid droplet formation gene expression in DKO mice. In contrast to TH-signaling, both NCoR and SMRT appear to be required for this steatotic program. Interestingly, the phenotype and gene expression profile of DKO mice closely parallels that found in mice which lack HDAC3 in the liver.Taken together these data demonstrate that co-repressor specificity exists in vivo as NCoR plays a specific role in TH signaling that cannot be compensated for by SMRT. In contrast, both NCoR and SMRT control hepatic lipogenesis and lipid droplet formation and are absolutely required for the actions of HDAC3.Highlighted Oral 2 Thyroid Hormone Metabolism & Regulation Thursday Highlighted Oral Basic 9:15 AMBOTH SKELETAL MYOCYTES AND ADIPOCYTES EXPRESS THE TYPE 2 DEIODINASE WITHIN SKELETAL MUSCLEJ.S. Werneck-de-Castro 1,2, T. Fonseca 1, D.L. Ignacio 2,3, G. Fernandes 1, M. Baldanza 2,3, I.F. Rangel 2,3, G. Balazs 4, M.F. Miranda 2,3, C. Andrade 1, A. Bianco 11Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL2School of Physical Education and Sports, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil3Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil4Endocrine and Neurobiology, Hungarian Academy of Science, Budapest, HungaryType 2 deiodinase (D2) is expressed in skeletal muscle (SKM) at low levels but it is thought to play a role in SKM biology. However, SKM has ectopic deposits of brown adipose tissue (BAT) that could be the source of local D2.To test this, we developed two new mice with tissue-specific D2 inactivation, i.e. SKM-D2KO or FAT-D2KO by crossing floxed Dio2 mice with the MLC-Cre or the AP2-Cre mice, respectively. In neonatal mice, all hind limb muscles (HLM) were dissected, pooled and processed for D2 activity. In adult mice the soleus muscle (SOL) was used: 200 ug total protein incubated for 3 h in PE buffer containing 20 mM DTT, 1 mM PTU and 0.1 nM 125I-T4 (100 nM for background); results expressed as fmol T4/mg/min; only littermate controls were used.HLM D2 activity was 40–50% lower in SKM-D2KO as well as in FAT-D2KO. At the same time, SOL D2 activity was ∼75% lower in SKM-D2KO and ∼70% in FAT-D2KO. SOL D2 mRNA levels were also lower in SKM-D2KO by ∼37% and in FAT-D2KO by ∼40%. BAT D2 activity did not change in SKM-D2KO mice but it was ∼65% lower in FAT-D2KO. Hypothyroidism (6 wks on LID+PTU) increased SOL D2 activity by about 8-fold in all animals. However, D2 mRNA was not affected given the predominant post-translational D2 regulation. We studied MyoD, Myh2, Pgc1a, Glut4 and Serca2 gene expression in SOL, and only the latter was ∼20% reduced in SKM-D2KO. The expression of a larger group of genes was not affected in SOL D2KO, in agreement with the finding of normal exercise running capacity in D2KO. When placed on a high fat diet for 8 wks, SKM-D2KO mice exhibited similar body weight, body composition, VO2 and RER as littermate controls. Serum levels of TSH, T4 and T3 were not different in the SKM-D2KO, but there was a ∼24% elevation in serum T4 in FAT-D2KO mice.In conclusion, D2 mRNA and activity in SKM reflect the combined expression in skeletal myocytes an
Referência(s)